1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
2
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Sunitinib versus interferon alfa in metastatic renal-cell
carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
3
|
Escudier B, Eisen T, Stadler WM, et al;
TARGET Study Group. Sorafenib in advanced clear-cell renal-cell
carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Shoji S, Nakano M, Sato H, Tang XY,
Osamura YR, Terachi T, Uchida T and Takeya K: The current status of
tailor-made medicine with molecular biomarkers for patients with
clear cell renal cell carcinoma. Clin Exp Metastasis. 31:111–134.
2013. View Article : Google Scholar : PubMed/NCBI
|
5
|
Deprimo SE, Bello CL, Smeraglia J, Baum
CM, Spinella D, Rini BI, Michaelson MD and Motzer RJ: Circulating
protein biomarkers of pharmacodynamic activity of sunitinib in
patients with metastatic renal cell carcinoma: modulation of VEGF
and VEGF-related proteins. J Transl Med. 5:322007. View Article : Google Scholar : PubMed/NCBI
|
6
|
Rini BI, Cohen DP, Lu DR, Chen I,
Hariharan S, Gore ME, Figlin RA, Baum MS and Motzer RJ:
Hypertension as a biomarker of efficacy in patients with metastatic
renal cell carcinoma treated with sunitinib. J Natl Cancer Inst.
103:763–773. 2011. View Article : Google Scholar
|
7
|
Clemons J, Gao D, Naam M, Breaker K,
Garfield D and Flaig TW: Thyroid dysfunction in patients treated
with sunitinib or sorafenib. Clin Genitourin Cancer. 10:225–231.
2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Wongkajornsilp A, Wamanuttajinda V,
Kasetsinsombat K, Duangsa-ard S, Sa-ngiamsuntorn K, Hongeng S and
Maneechotesuwan K: Sunitinib indirectly enhanced anti-tumor
cytotoxicity of cytokine-induced killer cells and
CD3+CD56+ subset through the co-culturing
dendritic cells. PLoS One. 8:e789802013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Gu Y, Zhao W, Meng F, Qu B, Zhu X, Sun Y,
Shu Y and Xu Q: Sunitinib impairs the proliferation and function of
human peripheral T cell and prevents T-cell-mediated immune
response in mice. Clin Immunol. 135:55–62. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Adotevi O, Pere H, Ravel P, et al: A
decrease of regulatory T cells correlates with overall survival
after sunitinib-based antiangiogenic therapy in metastatic renal
cancer patients. J Immunother. 33:991–998. 2010. View Article : Google Scholar
|
11
|
Rini BI, Escudier B, Tomczak P, et al:
Comparative effectiveness of axitinib versus sorafenib in advanced
renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet.
378:1931–1939. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
13
|
Lawicki S, Bedkowska GE, Gacuta-Szumarska
E, Knapp P and Szmitkowski M: Pretreatment plasma levels and
diagnostic utility of hematopoietic cytokines in cervical cancer or
cervical intraepithelial neoplasia patients. Folia Histochem
Cytobiol. 50:213–219. 2012. View Article : Google Scholar
|
14
|
Biancotto A, Wank A, Perl S, Cook W, Olnes
MJ, Dagur PK, Fuchs JC, Langweiler M, Wang E and McCoy JP: Baseline
levels and temporal stability of 27 multiplexed serum cytokine
concentrations in healthy subjects. PLoS One. 8:e760912013.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Dolcetti L, Peranzoni E, Ugel S, et al:
Hierarchy of immunosuppressive strength among myeloid-derived
suppressor cell subsets is determined by GM-CSF. Eur J Immunol.
40:22–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Serafini P, Mgebroff S, Noonan K and
Borrello I: Myeloid-derived suppressor cells promote
cross-tolerance in B-cell lymphoma by expanding regulatory T cells.
Cancer Res. 68:5439–5449. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Nagaraj S, Gupta K, Pisarev V, Kinarsky L,
Sherman S, Kang L, Herber DL, Schneck J and Gabrilovich DI: Altered
recognition of antigen is a mechanism of CD8+ T cell
tolerance in cancer. Nat Med. 13:828–835. 2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Xin H, Zhang C, Herrmann A, Du Y, Figlin R
and Yu H: Sunitinib inhibition of Stat3 induces renal cell
carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Cancer Res. 69:2506–2513. 2009. View Article : Google Scholar : PubMed/NCBI
|
19
|
Wang Y, Han G, Wang K, et al:
Tumor-derived GM-CSF promotes inflammatory colon carcinogenesis via
stimulating epithelial release of VEGF. Cancer Res. 74:716–726.
2014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Tran HT, Liu Y, Zurita AJ, et al:
Prognostic or predictive plasma cytokines and angiogenic factors
for patients treated with pazopanib for metastatic renal-cell
cancer: a retrospective analysis of phase 2 and phase 3 trials.
Lancet Oncol. 13:827–837. 2012. View Article : Google Scholar
|